Next Article in Journal
Relationship between Emotional Intelligence, Educational Achievement and Academic Stress of Pre-Service Teachers
Next Article in Special Issue
What Do We Know about Theory of Mind Impairment in Parkinson’s Disease?
Previous Article in Journal
Examining the Relationships among Cognitive Ability, Domain-Specific Self-Concept, and Behavioral Self-Esteem of Gifted Children Aged 5–6 Years: A Cross-Sectional Study
Previous Article in Special Issue
Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors

Lewy Body Dementias: A Coin with Two Sides?

Department of Neurology, Clínica Universidad de Navarra, 28027 Madrid, Spain
Department of Neurology, Clínica Universidad de Navarra, 31008 Pamplona, Spain
IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain
CIMA, Center of Applied Medical Research, Universidad de Navarra, Neurosciences Program, 31008 Pamplona, Spain
Author to whom correspondence should be addressed.
Academic Editors: Scott D. Lane and Carmen Gasca-Salas
Received: 12 May 2021 / Revised: 12 June 2021 / Accepted: 15 June 2021 / Published: 22 June 2021
(This article belongs to the Special Issue Parkinson’s Disease and Cognition)
Lewy body dementias (LBDs) consist of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), which are clinically similar syndromes that share neuropathological findings with widespread cortical Lewy body deposition, often with a variable degree of concomitant Alzheimer pathology. The objective of this article is to provide an overview of the neuropathological and clinical features, current diagnostic criteria, biomarkers, and management of LBD. Literature research was performed using the PubMed database, and the most pertinent articles were read and are discussed in this paper. The diagnostic criteria for DLB have recently been updated, with the addition of indicative and supportive biomarker information. The time interval of dementia onset relative to parkinsonism remains the major distinction between DLB and PDD, underpinning controversy about whether they are the same illness in a different spectrum of the disease or two separate neurodegenerative disorders. The treatment for LBD is only symptomatic, but the expected progression and prognosis differ between the two entities. Diagnosis in prodromal stages should be of the utmost importance, because implementing early treatment might change the course of the illness if disease-modifying therapies are developed in the future. Thus, the identification of novel biomarkers constitutes an area of active research, with a special focus on α-synuclein markers. View Full-Text
Keywords: Lewy body dementias; dementia with Lewy bodies; Parkinson disease dementia; diagnosis; biomarkers Lewy body dementias; dementia with Lewy bodies; Parkinson disease dementia; diagnosis; biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Milán-Tomás, Á.; Fernández-Matarrubia, M.; Rodríguez-Oroz, M.C. Lewy Body Dementias: A Coin with Two Sides? Behav. Sci. 2021, 11, 94.

AMA Style

Milán-Tomás Á, Fernández-Matarrubia M, Rodríguez-Oroz MC. Lewy Body Dementias: A Coin with Two Sides? Behavioral Sciences. 2021; 11(7):94.

Chicago/Turabian Style

Milán-Tomás, Ángela, Marta Fernández-Matarrubia, and María C. Rodríguez-Oroz 2021. "Lewy Body Dementias: A Coin with Two Sides?" Behavioral Sciences 11, no. 7: 94.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop